Method, device, and anti-photoaging and / or dermal pigmentation inhibitor for preventing and / or improving photoaging and / or dermal pigmentation, screening method for anti-photoaging and / or dermal pigmentation inhibitor, evaluation method for anti-photoaging and / or dermal pigmentation inhibition cosmetic treatment, and evaluation method for photoaging and / or dermal pigmentation degree
By adjusting the M1/M2 balance of macrophages and using specific compounds, combined with physical stimulation, the problems of photoaging and dermal pigmentation are solved, and effective prevention and improvement effects are achieved.
Patent Information
- Application Number
- CN202080029442.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-08-30
- Filing Date
- 2020-04-20
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2040-04-20
AI Technical Summary
The prior art is difficult to effectively prevent and improve photoaging and dermal pigmentation, and the existing anti-aging and pigmentation inhibitors have limited effects.
By adjusting the M1/M2 balance of macrophages, using faint physical stimuli such as skin stretching and compression, combined with compounds such as Forsythia extract, thyme extract, berberine and eucalyptus extract to prevent and improve photoaging and dermal pigmentation by adjusting the M1/M2 balance of macrophages, using faint physical stimuli such as skin stretching and compression, combined with compounds such as Forsythia extract, thyme extract, berberine and eucalyptus extract, to prevent and improve photoaging and dermal pigmentation. calm.
By adjusting M1/M2 balance, significantly improving the skin's photoaging and pigmentation status, it provides an objective evaluation method and an effective cosmetic treatment plan to prevent and improve photoaging and dermal pigmentation.
Smart Images

Figure CN113784753B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a method and device for preventing or improving photoaging and / or dermal pigmentation by adjusting the M1 / M2 balance, and an anti-photoaging and / or dermal pigmentation inhibitor, as well as a screening method for anti-photoaging and / or dermal pigmentation inhibitors using the M1 / M2 balance as an indicator, an evaluation method for anti-photoaging and / or dermal pigmentation inhibitory beauty treatments, and an evaluation method for photoaging and / or dermal pigmentation degree. Background Art
[0002] The aging phenomenon of human skin can be roughly divided into "natural aging" and "photoaging". Photoaging is a phenomenon observed specifically at the exposed part and is skin-specific. In photoaging, the generation of active oxygen and damage to the DNA of cells are induced by the influence of UV, etc., which damages the skin fiber tissue and is considered to be the cause of the appearance of phenotypes such as wrinkles and sagging. For example, through skin photoaging, phenomena such as the reduction of collagen fibers composed of collagen and the denaturation of elastic fibers composed of elastin are observed. In addition, melanocytes are also damaged, and a large amount of melanin pigment is formed, which becomes the cause of spots, etc.
[0003] In addition, pigmentation represented by spots and dark spots occurs by the accumulation of melanin produced by the melanocytes in the basal layer of the epidermis. Melanin is usually present in the epidermis and basal layer, but the epidermis is renewed in a relatively fast cycle, so such melanin is easily discharged. On the other hand, melanin is sometimes present in the dermis due to reasons such as melanin falling into the dermis from the gap of the basement membrane. The cycle of renewal of dermal cells is very slow compared with the epidermis, so such melanin is often not discharged and accumulated. Due to such reasons, the improvement of the pigmentation of the dermis is very difficult.
[0004] As an anti-photoaging beauty method, for example, Patent Document 1 discloses a method for preventing or inhibiting skin photoaging by preventing the inhibition of leukocyte elastase. Patent Document 2 discloses a photoaging inhibitor composition characterized by containing a plant extract of the genus Amaranthus of the Amaranthaceae family having a collagen synthesis promoting effect and a collagen peptide derived from an animal.
[0005] As a cosmetic method for improving pigmentation in the dermis, Non-Patent Document 13 proposes strengthening the basement membrane to prevent melanin from entering the dermis.
[0006] In addition, it is also suggested that inflammation is a cause of the photoaging phenomenon of the skin, and a large number of anti-inflammatory agents have been developed. Patent Document 3 discloses an anti-aging cosmetic composition containing a compound that induces autophagy activation as adiponectin expression increases. It is also suggested that the phagocytic action of macrophages is used to improve the pigmentation of the dermis, and Patent Document 15 discloses a dermal spot prevention / improvement agent that induces macrophages to phagocytize fibroblasts that have taken in melanin that has fallen into the dermis.
[0007] Prior art literature
[0008] Patent Literature
[0009] Patent Document 1: Japanese Patent No. 5657723
[0010] Patent Document 2: Japanese Patent Application Publication No. 2017-203004
[0011] Patent Document 3: Japanese Patent Application Publication No. 2018-177805
[0012] Patent Document 4: Japanese Patent Application No. 2014-504629
[0013] Patent Document 5: Japanese Patent Application Publication No. 2015-140334
[0014] Patent Document 6: Japanese Patent No. 6178088
[0015] Patent Document 7: Japanese Patent No. 6273304
[0016] Patent Document 8: Japanese Patent No. 5744409
[0017] Patent Document 9: Japanese Patent Application Publication No. 2018-140953
[0018] Patent Document 10: Japanese Patent Application Publication No. 2019-043855
[0019] Patent Document 11: Japanese Patent Application Publication No. 2013-053130
[0020] Patent Document 12: Japanese Patent Application Laid-Open No. 09-187248
[0021] Patent Document 13: Japanese Patent Application Publication No. 2003-261455
[0022] Patent Document 14: Japanese Patent Application Laid-Open No. 09-227367
[0023] Patent Document 15: Japanese Patent Application Publication No. 2018-072098
[0024] Patent Document 16: Japanese Patent No. 6535146
[0025] Patent Document 17: Japanese Patent Application Publication No. 2019-031482
[0026] Patent Document 18: Japanese Patent Application Publication No. 2007-063192
[0027] Non-patent literature
[0028] Non-patent document 1: Journal of the American College of Cardiology, Vol. 62, No. 20, 2013, November 12, 2013: 1890-901
[0029] Non-patent literature 2: Experimental & Molecular Medicine (2014) 46, e70; doi: 10.1038 / emm.2013.135
[0030] Non-patent document 3: NATURE, VOL495, 28 MARCH 2013, pp524-530, doi:10.1038 / nature11930
[0031] Non-patent document 4: Journal of Investigative Dermatology, 2009April; 129(4): 1016-25. Epub 2008Oct 9.
[0032] Non-patent literature 5: Stem Cell Research & Therapy (2018) 9:88, https: / / doi.org / 10.1186 / s13287-018-0821-5
[0033] Non-patent literature 6: Journal of the European Academy of Dermatology and Venereology 2011 European Academy of Dermatology and Venereology, 2012, 26, 1577-1580
[0034] Non-patent document 7: British Journal of Dermatology, 2005, 153, pp733-739
[0035] Non-patent document 8: Pigment Cell Melanoma Research, Vol. 27, Issue 3, pp502-504
[0036] Non-patent document 9: Ann Dermatol Vol.28, No.3, pp279-289, 2016
[0037] Non-patent literature 10: Endocrinology, 2011.152(10):pp3779-90
[0038] Non-patent document 11: British Journal of Dermatology, 2005.153Suppl 2:pp37-46
[0039] Non-patent document 12: Experimental Dermatology, 2011.20(11):pp953-5
[0040] Non-patent document 13: Fujifilm Research & Development (No. 55-2010): pp33-37 Summary of the invention
[0041] Problems to be solved by the invention
[0042] The object of the present invention is to provide a method and device for preventing and / or improving photoaging and / or dermal pigmentation, an anti-photoaging and / or dermal pigmentation inhibitor, a screening method for anti-photoaging and / or dermal pigmentation inhibitor, an evaluation method for anti-photoaging and / or dermal pigmentation inhibitory cosmetic treatments, and an evaluation method for photoaging and / or dermal pigmentation degree.
[0043] Methods for solving problems
[0044] The inventors have conducted in-depth research on the inhibitory effect of photoaging and dermal pigmentation, and found that the imbalance of the M1 / M2 balance of macrophages is related to photoaging and dermal pigmentation. Based on this discovery, an anti-photoaging and / or dermal pigmentation inhibitor for preventing and / or improving photoaging and / or dermal pigmentation, and an evaluation method for anti-photoaging and / or dermal pigmentation inhibition beauty treatment have been established. Through such a method, a new beauty method, device, and anti-photoaging and / or dermal pigmentation inhibitor that exert an anti-photoaging and / or dermal pigmentation inhibitory effect have also been developed.
[0045] Thereby completing the following invention:
[0046] (1) A cosmetic method for preventing and / or improving photoaging and / or dermal pigmentation by adjusting the M1 / M2 balance.
[0047] (2) According to the method described in (1), adjusting the M1 / M2 balance is to increase the ratio of M2 to M1.
[0048] (3) The method according to (1) or (2), wherein adjusting the M1 / M2 balance comprises a step of applying a weak physical stimulus to the skin, wherein the step is achieved by, for example, applying a physical stimulus to the subject's skin in a cycle at a frequency of 60 Hz or less, wherein the cycle comprises the following steps:
[0049] (a) stretching the skin of the subject to a stretch ratio of 0.1% to 50.0%; and
[0050] (b) recovery from stretch;
[0051] and / or,
[0052] (a-1) pressing the skin of the subject by 1 μm to 1000 μm; and
[0053] (b-1) restoring the skin of the subject from a compressed state;
[0054] The elongation is calculated by the following formula:
[0055]
[0056] (wherein, fixed point A and fixed point B are any positions on the epidermis or the substrate to which the epidermis is bonded, and the straight line passing through fixed point A and fixed point B is parallel to the stretching direction)
[0057] (4) A beauty device is a beauty device used to prevent and / or improve photoaging and / or dermal pigmentation by adjusting the M1 / M2 balance,
[0058] The above device has:
[0059] a stimulus generating part for generating physical stimulus, and
[0060] a stimulation applying section for applying the physical stimulation generated by the stimulation generating section to the skin,
[0061] The device is a device for performing a process of applying weak physical stimulation to the skin, wherein the process is, for example, cycled at a frequency of less than 60 Hz, and the cycle includes the following steps:
[0062] (a) stretching the skin to a stretch ratio of 0.1% to 50.0%; and
[0063] (b) recovery from stretch;
[0064] and / or,
[0065] (a-1) pressing the skin of the subject by 1 μm to 1000 μm; and
[0066] (b-1) restoring the skin of the subject from a compressed state;
[0067] Here, the elongation ratio is calculated by the above-mentioned formula 1.
[0068] (5) A method for screening an anti-photoaging and / or dermal pigmentation inhibitor, the method comprising the following steps:
[0069] administering a candidate agent to a biological sample;
[0070] Determining the M1 / M2 balance in a biological sample before and after administration of a candidate drug; and
[0071] When the M1 / M2 balance in the biological sample to which the candidate drug is administered is improved compared to before administration of the drug, the drug is evaluated to have an anti-photoaging and / or dermal pigmentation inhibitory effect.
[0072] (6) A method for evaluating anti-photoaging and / or dermal pigmentation inhibition cosmetic treatments, the method comprising the following steps:
[0073] Applying cosmetic treatment to skin samples;
[0074] Determining the M1 / M2 balance in skin samples before and after cosmetic treatment; and
[0075] When the M1 / M2 balance in the skin sample subjected to the cosmetic treatment is improved compared to that before the treatment, the treatment is evaluated to have an anti-photoaging and / or dermal pigmentation inhibitory effect.
[0076] (7) A method for evaluating photoaging and / or dermal pigmentation, which is performed by one or more computers, and the method comprises the following steps:
[0077] A step of acquiring data regarding a preset reference value of the M1 / M2 balance of the skin;
[0078] The step of obtaining data regarding the M1 / M2 balance of the subject's skin;
[0079] The step of calculating by referring to the reference value and comparing with the data on the M1 / M2 balance of the subject's skin;
[0080] A step of evaluating the photoaging and / or dermal pigmentation inhibition degree of the skin based on the calculation result obtained by the calculation step; and
[0081] A step of displaying the evaluation result obtained by the above-mentioned evaluation step.
[0082] (8) A system for evaluating photoaging and / or dermal pigmentation, the system comprising:
[0083] A database unit storing data on a preset reference value of the M1 / M2 balance of the skin;
[0084] a data input section for inputting data on the M1 / M2 balance of the subject's skin;
[0085] a calculation unit for performing calculation by comparing the data on the M1 / M2 balance of the subject's skin inputted through the data input unit with the reference value stored in the database unit;
[0086] An evaluation unit for evaluating the photoaging of the skin and / or the degree of dermal pigmentation based on the calculation result obtained by the calculation unit; and
[0087] A display unit displays the evaluation result obtained by the evaluation unit.
[0088] (9) A screening kit for anti-photoaging and / or dermal pigmentation inhibitors, comprising an agent for determining the M1 / M2 balance.
[0089] (10) Anti-photoaging and / or dermal pigmentation inhibitors, which are used to prevent and / or improve photoaging and / or dermal pigmentation by adjusting the M1 / M2 balance.
[0090] (11) The anti-photoaging and / or dermal pigmentation inhibitor according to (10), comprising: a compound represented by the following general formula (1) or a salt thereof, a Forsythia suspensa extract, a Thyme extract, a Phellodendron amurense, and / or a Eucalyptus extract.
[0091]
[0092] {wherein, R1 and R2 are the same or different and each represents a hydrogen atom, a linear or branched alkyl group having 1 to 18 carbon atoms, a cycloalkyl group having 5 to 8 carbon atoms, a benzyl group or the following general formula (2),
[0093]
[0094] (wherein X represents a lower alkyl group, a lower alkoxy group, a hydroxyl group, an amino group, or a halogen atom, and n=0 to 3)}
[0095] (12) An M1 / M2 balance adjusting / improving agent comprising: a compound represented by the following general formula (1) or a salt thereof, a Forsythia suspensa extract, a Thyme extract, a Phellodendron amurense, and / or a Eucalyptus extract.
[0096]
[0097] {wherein, R1 and R2 are the same or different and each represents a hydrogen atom, a linear or branched alkyl group having 1 to 18 carbon atoms, a cycloalkyl group having 5 to 8 carbon atoms, a benzyl group or the following general formula (2),
[0098]
[0099] (wherein X represents a lower alkyl group, a lower alkoxy group, a hydroxyl group, an amino group, or a halogen atom, and n=0 to 3)}
[0100] (13) A composition comprising the drug according to any one of (10) to (12).
[0101] (14) The method according to (1) or (2), wherein the adjustment of the M1 / M2 balance is achieved by administering the agent described in any one of (10) to (12).
[0102] Effects of the Invention
[0103] Through the method, device, and agent of the present invention, photoaging and / or dermal pigmentation can be prevented and / or improved by adjusting the M1 / M2 balance. In addition, by using the M1 / M2 balance as an indicator, photoaging and / or dermal pigmentation can be objectively evaluated, and based on such a method, agents and cosmetic treatments for preventing and / or improving photoaging and / or dermal pigmentation can be explored. BRIEF DESCRIPTION OF THE DRAWINGS
[0104] Figure 1a The types of macrophage markers used in Experiment 1, and the age, skin type, and gender of the subjects are shown.
[0105] Figure 1b These are microscopic photographs showing macrophages (CD11b: red) and M1 macrophages (CD86: green) in the skin tissues of young and elderly people.
[0106] Figure 1c These are microscopic photographs showing macrophages (CD11b: red) and M2 macrophages (CD206: green) in the skin tissues of young and elderly people.
[0107] Figure 1d The figure shows the number of M1 and M2 macrophages and the total number of macrophages in the skin tissue of young and old people (cells / mm 2 ).
[0108] Figure 1eThe left image is a microscope photograph showing co-staining of M1 macrophages (CD86: red) or M2 macrophages (CD206: red) and procollagen (green) in the skin tissue of young and old people. The rectangles in each of the four sections in the left image are magnified images of characteristic sites. Figure 1e The figure on the right is a schematic diagram of the relationship between M1, M2, fibroblasts, and collagen production / destruction.
[0109] Figure 2a An outline of the method for Experiment 2 is shown.
[0110] Figure 2b These are microscopic photographs of M0, M1, and M2 macrophages induced in Experiment 2.
[0111] Figure 2c The upper graph shows the gene expression levels of cytokines (IL-1beta, TNF-alpha, IL-10) produced by M0, M1, and M2 macrophages induced in Experiment 2. Figure 2c The lower figure shows the expression levels of mRNA of cell surface markers of M1 and M2 macrophages (M1: CD86, M2: CD206). The expression levels were corrected using the mRNA expression level of GAPDH and shown as relative values (%) with M0 being 100%.
[0112] Figure 3a An outline of the method of Experiment 3 is shown.
[0113] Figure 3b The amount of procollagen in fibroblasts to which the supernatants of M1 and M2 macrophages were added according to Experiment 3 (μg / well) is shown.
[0114] Figure 3c This is a microscopic photograph showing collagen (red) and hyaluronic acid (green) in fibroblasts to which the supernatant of M1 and M2 macrophages was added according to Experiment 3.
[0115] Figure 3d This is a micrograph showing β-galactosidase (β-Gal) in fibroblasts to which supernatants of M1 and M2 macrophages were added according to Experiment 3.
[0116] Figure 3e The graph shows the results of the aging-associated β-galactosidase (SAβ-Gal) assay in fibroblasts to which the supernatant of M1 and M2 macrophages was added according to Experiment 3 (left graph: the ratio (%) of SAβ-gal-positive cells to the total number of DAPI-positive cells), and the total number of DAPI-positive cells per well (right graph).
[0117] Figure 3fThe graph shows the mRNA expression levels of melanogenesis enhancing factors (HGF, ET1, bFGF, IL-1alpha, SCF) and melanogenesis inhibiting factors (clusterin, DKK1) in fibroblasts to which supernatants of M1 and M2 macrophages were added according to Experiment 3.
[0118] Figure 4a These are microscopic photographs showing β-Gal in young and old fibroblasts to which supernatants of M1 and M2 macrophages were added according to Experiment 4.
[0119] Figure 4b The graph shows the results of the SAβ-Gal assay in young (upper) and old fibroblasts (lower) to which supernatants of M1 and M2 macrophages were added according to Experiment 4 (the ratio (%) of SAβ-gal-positive cells to the total number of DAPI-positive cells) and the total number of DAPI-positive cells per well.
[0120] Figure 4c The amount of procollagen (μg / well) in young and old fibroblasts to which supernatants of M1 and M2 macrophages were added according to Experiment 4 is shown.
[0121] Figure 4d These are microscopic photographs showing collagen (red) and nuclei stained with DAPI (blue) in young and old fibroblasts to which supernatants of M1 and M2 macrophages were added according to Experiment 3.
[0122] Figure 5 These are microscopic photographs showing type I collagen (red) and macrophages (CD68: green) in neonatal foreskin-derived fibroblasts to which supernatants of M1 and M2 macrophages were added according to Experiment 5. The upper left photograph shows fibroblasts cultured without addition of supernatants of macrophages.
[0123] Figure 6 The micrographs show macrophages (CD68: red) and M1 macrophages (CD86: green) or M2 macrophages (CD206: green) in the 3D model prepared according to Experiment 6. The triangle-denoted portion shows a portion doubly stained with CD68 and CD86 or CD68 and CD206.
[0124] Figure 7 This is a microscopic photograph showing p21 (red) and nuclei stained with DAPI (blue) in the 3D model prepared according to Experiment 6.
[0125] Figure 8This is a graph showing the ratio (%) of the number of p21-positive cells in each layer of the 3D model prepared according to Experiment 6 (left: upper layer = epidermal cell layer, right: lower layer = fibroblast layer) to the total number of cells.
[0126] Fig. 9 This is a graph showing the number of total macrophages, M1 macrophages, and M2 macrophages in the ex vivo skin model irradiated with the solar simulator according to Experiment 7. The number of each macrophage without irradiation is set to 100% (left bar: irradiation (-)), and the relative value (%) of the number of each macrophage irradiated thereto is shown in the right bar (irradiation (+)).
[0127] Fig.10 The setting of the stretch stimulation performed in Experiment 8 is shown.
[0128] Fig.11 The apparatus and skin specimens used in Experiment 8 are shown.
[0129] Fig.12 The figure shows the comparison of the number of M1, M2 macrophages and the total number of macrophages in the case where stretch stimulation was applied to the ex vivo skin model (stretch) and the case where no stretch stimulation was applied (control) according to Experiment 8. The left figure shows the number of M1, M2 macrophages and the total number of macrophages per 1 mm 2 The number of macrophages in skin samples (cells / 1mm 2 ). The right figure is a graph showing the ratio (%) of each macrophage (M1, M2) to the total number of all macrophages.
[0130] Fig.13 The results of the screening performed in Experiment 9 are shown. The bars are graphs showing the CD86 expression levels (CD86 / GAPDH values) when various concentrations of a Forsythia suspensa extract (0.1%), a thyme extract (0.1%), and tranexamic acid carboxamide (0.03%, 0.06%) were added, respectively, as relative values (%) when the control (cont) was set to 100%.
[0131] Fig.14 An example of the device of the present invention is shown.
[0132] Fig.15 The results of the screening performed in Experiment 10 are shown. The bars are graphs showing the CD86 expression levels (CD86 / GAPDH values) when various concentrations of Phellodendron amurense extract (0.01%) and Eucalyptus extract (0.1%) were added, as relative values (%) with the control (cont) being 100%.
[0133] Fig.16aThe graph shows the mRNA expression levels of various collagenases (MMP-1, MMP-2) and inflammatory cytokines (IL-1β) in fibroblasts to which supernatants of M1 and M2 macrophages were added according to Experiment 11, as relative values (%) when the result of M1 was set to 100%.
[0134] Fig.16b The graph shows the mRNA expression levels of various collagen production / maturation factors (COL1A1, COL1A2, HSP47, and ADAMTS-2) in fibroblasts to which supernatants of M1 and M2 macrophages were added according to Experiment 11, as relative values (%) when the result of M1 was set to 100%.
[0135] Fig.17a The ages of the subjects from whom the samples in Experiment 12 were obtained are shown in the younger and older groups.
[0136] Fig.17b This is a graph showing the number of M1 and M2 macrophages in the skin tissue (50 μm just below the basement membrane) of young and old people in Experiment 12 (cells / mm 2 ).
[0137] Fig.17c This is a graph showing the number of M1 and M2 macrophages in the skin tissue (200 μm just below the basement membrane) of young and old people in Experiment 12 (cells / mm 2 ).
[0138] Fig.17d This is a graph showing the number of CD68-negative cells, M1 and M2 macrophages, which are positive for 3 / 4 collagen, in the skin tissues of young and elderly people in Experiment 12 (cells / mm 2 ).
[0139] Fig.18a The figure shows the appearance of fibroblasts, M1 macrophages, and M2 macrophages 24 hours after the addition of melanin in Experiment 13. The cells that have engulfed melanin have a round shape as shown in the right figure.
[0140] Fig.18b The graph shows the amount of melanin taken up per cell by fibroblasts, M1 macrophages, and M2 macrophages 24 hours after the addition of melanin in Experiment 13 (melanin / alamar blue).
[0141] Fig.18c The images of M1 macrophages and M2 macrophages 5 days after the addition of melanin in Experiment 13 are shown.
[0142] Fig.19The upper graph shows the number of melanin-phagocytic M1 macrophages and M2 macrophages in the dermis layer counted according to Experiment 14 for each age. Fig.19 The numbers of melanophagocytic M1 macrophages and M2 macrophages are shown below as the average of all subjects. DETAILED DESCRIPTION
[0143] It is known that macrophages are cells that are locally present in various tissues in the body and cause immune responses to foreign bodies and pathogens, and are also involved in inflammation. Macrophages differentiate from undifferentiated M0 macrophages (hereinafter sometimes abbreviated as M0) into M1 type and M2 type. M1 macrophages (hereinafter sometimes abbreviated as M1) are known as inflammatory type, and M2 macrophages (hereinafter sometimes abbreviated as M2) are known as repair type (anti-inflammatory type). It is reported that the imbalance of the balance between M1 macrophages and M2 macrophages is associated with diseases such as obesity, type 2 diabetes, and arteriosclerosis (patent documents 4 to 6, non-patent documents 1 to 5). However, the relationship between skin photoaging, pigmentation and M1 / M2 balance is unclear.
[0144] The inventors have found that the balance of these M1 macrophages and M2 macrophages (M1 / M2 balance) is specifically disturbed in the skin exposed to light and the site where pigmentation occurs, and adjusting the M1 / M2 balance is particularly important in the prevention and improvement of photoaging and pigmentation. Furthermore, the inventors have also found that if the M1 / M2 balance is used as an indicator of skin photoaging and pigmentation, a satisfactory effect is exerted by applying a specific physical stimulus to the skin of the subject. More specifically, it can be seen that even for photoaged skin and pigmented skin, if a physical stimulus is applied at a specific extension rate, for example, at a frequency of less than 60 Hz such as less than 1 Hz or less than 10 Hz, the M1 / M2 balance is adjusted / improved. In addition, the inventors screened various substances using M1 / M2 balance as an index of skin photoaging and pigmentation, and found that the extract of Forsythia suspensa, the compound of the present invention represented by tranexamic acid carboxamide, thyme extract, Phellodendron amurense, and eucalyptus extract have the effect of adjusting / improving the M1 / M2 balance, and function as an anti-photoaging agent and an anti-pigmentation agent. The Forsythia suspensa extract has been reported to promote the production of type I collagen and to promote hair growth (patent documents 9, 10). The compound of the present invention represented by tranexamic acid carboxamide has been reported to improve skin roughness, whiten skin, and resist allergic reactions (patent documents 11, 14, etc.). The extract of thyme has been reported to resist allergic reactions and antibacterial effects (patent documents 12, 13). Phellodendron chinense is also used as an antidiarrheal medicine, stomach medicine, an internal medicine for indigestion and loss of appetite, or an external medicine for traumatic injuries and sprains, and has also been reported to have antibacterial, antioxidant, skin barrier function improvement effects, pigment cell activation effects, etc. (Patent Documents 16 and 17). Eucalyptus extract has been reported to have antibacterial and antioxidant effects, etc. (Patent Document 18). However, it is the first time for the inventors to discover that these substances have the effect of adjusting / improving the balance of M1 / M2.
[0145] Therefore, the present invention provides a method, device, and anti-photoaging and / or pigmentation inhibitor for preventing and / or improving photoaging and / or pigmentation by adjusting the M1 / M2 balance. The method of the present invention is a method for beauty purposes, and sometimes it is not a treatment performed by a doctor or medical practitioner.
[0146] In this specification, pigmentation refers to the deposition of pigments such as melanin in the dermis and epidermis. The present invention is effective in both the dermis and the epidermis, and is particularly expected as a countermeasure for pigmentation in the dermis, in the sense that the improvement method is limited except for phagocytosis by melanophages. Through the application of the preparation of the present invention, spots, dullness, dark circles, etc. caused by pigmentation are improved. In addition, it is also effective for the decolorization of tattoos, tattoos, etc., which are difficult to eliminate once the pigment is added due to the injection of pigment into the dermis.
[0147] M1 macrophages can be measured using markers such as CD86, CD80, and iNOS. M2 macrophages can be measured using markers such as CD206, CD163, and Agr1. As markers for all macrophages including M1 and M2, CD11b, CD68, and the like can be cited. In addition or alternatively, it can be measured by quantifying M1-specific cytokines such as IL-1beta and TNF-alpha, and M2-specific cytokines such as IL-10. However, as long as it is a marker that can measure the M1 / M2 balance, it is not limited to the above markers.
[0148] In the present specification, the so-called M1 / M2 balance may refer to the ratio of the number of M1 macrophages to the number of M2 macrophages, or the ratio of the mRNA amount of M1 macrophage markers (e.g., CD86, CD80, iNOS, etc.) to the mRNA amount of M2 macrophage markers (e.g., CD206, CD163, Agr1, etc.). In the photoaged skin, the ratio of M1 is high and the ratio of M2 is low, and M2 has a high melanophage activity, so the adjustment / improvement of the M1 / M2 balance may be to increase the ratio of M2 to M1 (the number of M2 / the number of M1, and / or the mRNA amount of M2 markers / the mRNA amount of M1 markers). The increase may be, for example, an increase with a statistically significant difference (e.g., Student's t-test) at a significance level of 5%, and / or may be, for example, an increase of 1% or more, 5% or more, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, or 100% or more. Or the adjustment / improvement of the M1 / M2 balance may be such that the ratio of M2 to M1 (the number of M2 / the number of M1, and / or the amount of mRNA of the M2 marker / the amount of mRNA of the M1 marker) is within a certain range, for example, about 4 / 6 to about 9 / 1, about 5 / 5 to about 8 / 2, about 5 / 5 to about 7 / 3, etc., and may be close to the above range, or maintained within the above range, or maintained in a steady state with the above range as the center.
[0149] The adjustment / improvement of the M1 / M2 balance can be achieved by applying physical stimulation such as stretching stimulation, pressing stimulation, and massage to the skin. The adjustment / improvement of the M1 / M2 balance includes a process of applying a weak physical stimulation to the skin. The device of the present invention is a device for performing a process of applying a weak physical stimulation to the skin, wherein the process can be cycled at a frequency of, for example, 60 Hz or less, and the cycle includes the following steps: (a) stretching the skin to a stretching rate of 0.1% to 50.0%; and (b) recovering from the stretched state.
[0150] The stretch rate is calculated by the above formula 1. Physical stimulation can be performed at a stretch rate of 0.001% to 80.0%, 0.01% to 60.0%, 0.1% to 50.0%, preferably 0.1% to 50.0%. For example, any range of stretch rates such as 0.1% to 1.0%, 0.1% to 5.0%, 0.1% to 10.0%, 0.1% to 20.0%, 0.1% to 30.0%, 1.0% to 5.0%, 1.0% to 10.0%, 1.0% to 20.0%, 1.0% to 30.0%, 1.0% to 50.0%, 10.0% to 20.0%, 10.0% to 30.0% can be used.
[0151] The stretching speed refers to the speed (% / s) until the maximum stretching rate (%) is reached in one cycle. The recovery rate refers to the speed (% / s) of recovery from the maximum stretching rate to the non-stretched state. The stretching speed / recovery speed can be any speed such as 0.010% / s to 40% / s, 0.05% / s to 30% / s, 0.10% / s to 20% / s, 0.2% / s to 15% / s, 0.3% / s to 10% / s. The stretching speed and the recovery speed can be the same or different.
[0152] Adjustment / improvement of M1 / M2 balance includes a process of applying weak physical stimulation to the skin. The device of the present invention is a device for performing a process of applying weak physical stimulation to the skin, wherein the process can be cycled at a frequency of less than 60 Hz, for example, and the cycle includes the following steps: (a-1) pressing the skin of the object by 1 μm to 1000 μm; and (b-1) restoring the skin of the object from the pressed state.
[0153] The so-called "pressing the skin 1 μm to 1000 μm" means pressing the skin to a depth of 1 μm to 1000 μm from the outermost surface of the skin. The pressing depth can be arbitrarily set to 1 μm to 1000 μm, 10 μm to 1000 μm, 10 μm to 300 μm, 10 μm to 100 μm, etc. from the outermost surface of the skin.
[0154] Frequency refers to the number of cycles per second when the cycle of returning to the non-stretched or non-pressed state from the start of stretching or pressing is set as 1 cycle. In 1 cycle, it may include maintaining the stretching or pressing state for a certain period of time and / or pausing in the non-stretched or non-pressed state. For example, in 1 cycle, it may further include: (a') after (a) and before (b), or after (a-1) and before (b-1), maintaining the stretching or pressing state for 0 seconds to 30 minutes, 1 second to 20 minutes, 5 seconds to 10 minutes, or 10 seconds to 5 minutes; and / or (b') after (b) and before (a) of the next cycle, or after (a-1) and before (b-1), pausing in the non-stretched or non-pressed state for 0 seconds to 30 seconds, 0 seconds to 20 seconds, 0 seconds to 10 seconds, 1 second to 10 seconds, 1 second to 20 seconds, 1 second to 10 seconds. The frequency may be, for example, 0.0000001 Hz to 10 kHz, 0.000001 Hz to 1 kHz, or 0.00001 Hz to 100 Hz, and preferably 0.0001 Hz to 60 Hz, or 0.0001 Hz to 10 Hz. Any frequency range may be employed, for example, 0.001 Hz to 60 Hz, 0.01 Hz to 60 Hz, 0.001 Hz to 10 Hz, 0.01 Hz to 10 Hz, 0.1 Hz to 60 Hz, 0.1 Hz to 10 Hz, 0.5 Hz to 60 Hz, 0.5 Hz to 50 Hz, 0.5 Hz to 10 Hz, 0.5 Hz to 5 Hz, 0.5 Hz to 1 Hz, 0.001 Hz to 0.01 Hz, 0.001 Hz to 0.1 Hz, 0.001 Hz to 1 Hz, 0.01 Hz to 1 Hz, 0.1 Hz to 1 Hz, 1 Hz to 60 Hz, 1 Hz to 10 Hz, 1 Hz to 5 Hz.
[0155] Among the facial beautification devices and massage equipment on the market, there are those that use electromagnetic waves with a frequency of about 0.3 to 300 MHz, such as RF waves, and those that use ultrasonic waves with a frequency of about 1 MHz to 7 MHz. Compared with these frequencies, the frequency used by the method / device of the present invention is extremely low. If a strong frequency is applied to the skin as in the past facial beautification devices, there is a risk of causing adverse effects such as redness, indentation, injury, pain, and inflammation to the skin, but if the frequency of the present invention is used, the above risks are low, and non-invasive physical stimulation can be performed. This is because the inventors have found that if the stretch rate and frequency are too high, the stimulation is too strong, so by adjusting these values to appropriate values, it is more satisfactory to gently stimulate the skin.
[0156] In addition, in the past, for beauty equipment that generally uses components such as electric motors in this field, it is common knowledge among those skilled in the art that only frequencies exceeding 60 Hz can be selected based on the mechanical components of the electric motor. When using frequencies below "60 Hz" that are the limit of beauty equipment in the prior art, such as frequencies below 60 Hz, below 10 Hz, and below 1 Hz, as in the present invention, it is necessary to produce special machinery. Furthermore, for such low frequencies, there is also a fixed concept that the effect of the present invention is "too weak", and there has been almost no research to date. However, the inventors tried to actually apply physical stimulation to the skin using very low frequencies that were considered common knowledge based on the past, and surprisingly, even such mild stimulation at such a low frequency exerted a good effect.
[0157] Although low-medium frequency devices such as EMS equipment are also commercially available, they are particularly designed to act on deep layers such as muscles and subcutaneous fat, and their effects on the surface of the skin such as the present invention are unclear. In addition, even if such devices have low frequencies, they are sometimes accompanied by a tingling stimulation when current flows through them, which is different from the present invention that applies a gentle stimulation to the skin. On the other hand, the present invention can be a beauty method that is performed by a simple method of directly applying stretch stimulation to the skin without applying energy such as ultrasound, electric current, and magnetic field. Furthermore, stretch stimulation with such a frequency is a gentle stimulation, and plays a role in adjusting / improving the M1 / M2 balance as described in the examples. Therefore, if the method / device of the present invention is used, it will not have an adverse effect on the skin, and the prevention and / or improvement effect of photoaging and / or pigmentation can be expected.
[0158] Physical stimulation can be physical stimulation generated by instruments such as beauty devices, experimental devices, massage using human hands and instruments, facial movements, and can also be physical stimulation achieved through contact or non-contact. In one embodiment, a device having a stimulation generating part that generates physical stimulation and a stimulation applying part that applies physical stimulation through contact or non-contact can be used to apply mechanical physical stimulation to the skin. Physical stimulation can be achieved, for example, by contact such as stretching, pressing, tapping, kneading, and sucking the skin, and / or can be achieved, for example, by non-contact such as applying shock waves to the skin using ultrasound, air pressure, or water pressure to displace it. As facial movements, the cheeks can be puffed up, the eyes can be opened, etc. As massage, massage using instruments such as hands and rollers performed by the subject being treated or by a beauty therapist can be cited. However, there is no limitation as long as it is within the scope of the physical stimulation of the present invention.
[0159] As the device of the present invention, for example, there can be mentioned a beauty device having a skin contact part that contacts the skin of the user to apply the physical stimulation of the present invention. For example, it can be a device composed of a gripping part and a skin stretching part or a skin pressing part. For example, Fig.14 The device described on the left is designed to come into contact with the skin via a skin contact portion, thereby stretching the skin at a specific frequency and stretching rate.
[0160] In addition, for example, the device of the present invention includes a power supply, a stimulation generating unit, and a skin stimulation unit. The power supply generates an electrical signal, the stimulation generating unit converts the electrical signal from the power supply into a physical stimulus to generate a physical stimulus, and the skin stimulation unit can receive the physical stimulus generated by the stimulation generating unit and apply the physical stimulus to the user's skin.
[0161] For example, Fig.14 The device shown on the left includes a gripping portion, a power source, a control portion for controlling physical stimulation, a stimulation generating portion, and a skin contact portion including a skin stimulation portion and a skin fixing portion. It is designed in the following manner: the user holds the gripping portion and places the skin contact portion on the skin, fixes the skin through the skin fixing portion, and operates the control portion so that the electrical signal from the power source is converted into a physical stimulation by the stimulation generating portion, and the physical stimulation is transmitted to the skin stimulation portion, and the skin is fixed to the skin fixing portion and stretched at a specific frequency and stretching rate through the skin stimulation portion. For example, the stimulation generating portion may be a portion that is driven by a motor or the like and converts the electrical signal into a physical stimulation. In addition, Fig.14 The skin stimulation part described on the left applies extension stimulation to the skin, for example, it may apply compression stimulation to the skin.
[0162] Alternatively, the device of the present invention may be a beauty device comprising a power source, a control unit for controlling physical stimulation, a stimulation generating unit, and a skin contacting unit including a skin contacting surface formed of a sheet material. Fig.14 The skin contact part of such a beauty device is shown on the right. The sheet material can be a material that can flow current and convert the electrical signal from the power supply into a physical stimulus. Examples of such sheet materials include dielectric elastomer actuators (DEA), conductive polymers, IPMC, PVC gel, and Mckinnen type.
[0163] The power source of the device of the present invention can be an internal power source or an external power source, or can be a rechargeable type. In addition, the device of the present invention can use data stored in a mobile phone, cloud, etc., or can be remotely operated wirelessly.
[0164] Physical stimulation can be stimulation that stretches the skin by applying physical stimulation such as the above-mentioned physical stimulation performed by contact or non-contact. Physical stimulation can be applied in a parallel direction relative to the skin surface, that is, in a horizontal direction, or in a vertical direction relative to the skin surface, that is, in a longitudinal direction, or in any direction such as an inclined direction or a twisted direction.
[0165] The number of cycles of physical stimulation is not limited. For example, any number of cycles such as 10 to 500 cycles, 20 to 400 cycles, 30 to 300 cycles, 40 to 200 cycles, or 50 to 100 cycles may be performed. For example, as described in the examples, 27 cycles may be sufficient.
[0166] Furthermore, any number of cycles may be set as one set, and the set may be repeated in any number of sets, for example, 1 to 100 sets, 2 to 50 sets, or 3 to 10 sets.
[0167] The duration of physical stimulation is also not limited. For example, the physical stimulation may be repeated with or without a pause time for a certain period of time such as 5 minutes to 3 hours, 10 minutes to 2 hours, or 30 minutes to 1 hour.
[0168] There is no limit to the time interval between cycles or groups. For example, stretching or pressing stimulation can be performed alone in one or more groups, or one or more groups can be performed once a day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, once every 1, 2, 3, 4 weeks, etc., continuously or intermittently, regularly or irregularly.
[0169] However, as long as sufficient stimulation is achieved to exert the skin anti-photoaging and / or pigmentation inhibition effect, it is not limited to the above-mentioned frequency, extension rate, number of cycles, and frequency. The waveform of physical stimulation can also be arbitrarily set to a rectangular wave, a sine wave, a triangle wave, a sawtooth wave, etc.
[0170] Alternatively, the adjustment / improvement of M1 / M2 balance can be to apply M1 / M2 balance adjustment / improvement agent or a composition containing it. The inventors found that the compound of the present invention, the Fructus Forsythiae extract, the Thyme extract, the Phellodendron chinense, and / or the Eucalyptus extract function as such an M1 / M2 balance adjustment / improvement agent. Therefore, the present invention also provides a composition consisting of the compound of the present invention, the Fructus Forsythiae extract, the Thyme extract, the Phellodendron chinense, and / or the Eucalyptus extract, or comprising the compound of the present invention, the Fructus Forsythiae extract, the Thyme extract, the Phellodendron chinense, and / or the Eucalyptus extract as an active ingredient M1 / M2 balance adjustment / improvement agent, an anti-photoaging agent, a pigmentation inhibitor, and a composition containing them.
[0171] In the present specification, "the compound of the present invention" refers to a compound represented by the following general formula (1) or a salt thereof.
[0172]
[0173] {wherein, R1 and R2 are the same or different and each represents a hydrogen atom, a linear or branched alkyl group having 1 to 18 carbon atoms, a cycloalkyl group having 5 to 8 carbon atoms, a benzyl group or the following general formula (2),
[0174]
[0175] (wherein X represents a lower alkyl group, a lower alkoxy group, a hydroxyl group, an amino group, or a halogen atom, and n=0 to 3)}
[0176] Particularly preferred compounds of the present invention are N-methyl-trans-4-(aminomethyl)cyclohexanecarboxamide (tranexamic acid carboxamide (C9H 19 C1N2O)) or its salt. The above compound can be synthesized by the method described in Patent Document 14, for example, or a commercially available product can be used.
[0177] Hypericum erectum is a perennial plant of the genus Hypericum in the family Garcinia. The extract of Hypericum erectum used in the present invention is preferably an extract of the aerial part of Hypericum erectum, but seeds, roots, etc. also contain active ingredients, so any one or more extracts thereof may be used. Commercially available extracts of Hypericum erectum may also be used.
[0178] Thyme (Thymus) is a perennial plant of the genus Thymus in the family Lamiaceae. In the present invention, various thymes such as common thyme (T. vulgaris), lemon thyme (Tx citriodorus), and Asian thyme (T. serpyllum) can be used. As the thyme extract used in the present invention, it is preferably an extract of the whole plant of thyme, but since seeds, flowers, roots, etc. also contain active ingredients, any one or more extracts thereof can also be used. Commercially available products can also be used for thyme extracts.
[0179] Phellodendron amurense is a herbal medicine obtained by drying the bark of Phellodendron amurense or Phellodendron chinense of the Rutaceae family. Phellodendron amurense or an extract thereof can be produced by a conventional method, or a commercially available product can be used.
[0180] Eucalyptus is a tree of the genus Eucalyptus of the Myrtaceae family. As the eucalyptus extract used in the present invention, an extract of the leaves of eucalyptus is preferred, but active ingredients are also contained in seeds, flowers, barks, roots, etc., so any one or more extracts thereof can also be used. The eucalyptus extract can be produced by conventional methods, or commercial products can be used.
[0181] When using an extract, the extraction method is not particularly limited, but an extraction method using a solvent is preferred. When performing the extraction, the plant body may also be used directly, but crushing it into a granular or powdered form and providing it for extraction can extract the effective ingredients with high extraction efficiency in a short time under mild conditions. The extraction temperature is not particularly limited and can be appropriately set according to the particle size of the crushed material, the type of solvent, etc. Usually, it is set within the range of room temperature to the boiling point of the solvent. In addition, the extraction time is not particularly limited and can be appropriately set according to the particle size of the crushed material, the type of solvent, the extraction temperature, etc. Further, during the extraction, stirring can be performed, or it can be left standing without stirring, and ultrasonic waves can be applied.
[0182] The type of solvent is not particularly limited, but preferably water, lower alcohols such as hydrous ethanol, ethanol, organic solvents such as hexane, or mixed solvents thereof such as hexane / ethanol. The extraction can be carried out at room temperature or under heating (for example, using a heated solvent such as warm water or hot water). In addition, an enzyme can be added to the solvent for extraction treatment. By adding an enzyme, the cell tissue of the plant can be disintegrated, thereby further improving the extraction efficiency. As the enzyme, a cell tissue maceration enzyme is preferably used. As such an enzyme, for example, pectinase, cellulase, hemicellulase, α-amylase, and phytase can be cited. These enzymes can be used alone or in combination of two or more.
[0183] By such extraction operation, the active ingredient is extracted and dissolved in the solvent. The solvent containing the extract can be used directly, or it can be used after applying conventional purification treatments such as sterilization, washing, filtering, decolorization, and deodorization. In addition, it can be used after concentration or dilution as needed. Further, the solvent can be completely volatilized and made into a solid state (dried product) before use, or the dried product can be used after being dissolved in any solvent again.
[0184] Furthermore, since a squeezed liquid obtained by squeezing a raw material plant also contains the same active ingredients as the extract, the squeezed liquid may be used instead of the extract.
[0185] However, the M1 / M2 balance adjusting / improving agent and composition are not limited to the above substances, and any substance can be used, for example, known substances for adjusting / improving the known M1 / M2 balance such as the substances described in patent documents 4 to 7. Its administration route can also be arbitrarily selected, such as transdermal administration, oral administration, subcutaneous administration, transmucosal administration, intramuscular administration, etc., but photoaging is a phenomenon specifically observed in the skin of the part exposed to light, so it is sometimes preferred to administer transdermally at a specific position of the skin. In addition, for pigmentation occurring in the epidermis and dermis, it is sometimes preferred to administer transdermally in a manner that can reach the epidermis and dermis from the skin. In addition, the adjustment / improvement of the M1 / M2 balance can be, for example, differentiation induction into M2 macrophages, or other arbitrary M1 / M2 balance adjustment / improvement methods can be used.
[0186] For example, the agent or composition of the present invention adjusts / improves the M1 / M2 balance, and as a result, inhibits photoaging and / or pigmentation of the skin. The M1 / M2 balance adjusting / improving agent, anti-photoaging agent, and pigmentation inhibitor of the present invention (hereinafter sometimes collectively referred to as "the preparation of the present invention") may contain any one of the above-mentioned active ingredients alone, or may contain two or more of them in any combination and ratio.
[0187] The preparation of the present invention can also be made into a composition in which the above-mentioned active ingredient is combined with one or more other ingredients such as excipients, carriers and / or diluents. The composition and form of the composition are arbitrary and can be appropriately selected according to the conditions such as the active ingredient and the purpose. The composition can be prepared by a conventional method using a prescription appropriately combined with excipients, carriers and / or diluents and other ingredients according to its dosage form.
[0188] The preparation of the present invention can be mixed with cosmetics and used for humans and animals, or can be administered to humans and animals as a pharmaceutical preparation. In addition, it can also be mixed with various foods and drinks and feeds for humans and animals to ingest.
[0189] When the present invention is applied to external skin preparations such as cosmetics, pharmaceuticals, and quasi-drugs, the amount of the plant or its extract (dry mass) to be mixed can be appropriately determined according to their type, purpose, form, method of use, etc. For example, the compound of the present invention, the Forsythia suspensa extract, the Thyme extract, the Phellodendron amurense extract, and / or the Eucalyptus extract can be mixed in an amount of 0.00001% to 50% (in the case of an extract or a crude drug, in dry mass conversion) in the total amount of the cosmetic.
[0190] In addition to the above-mentioned ingredients, ingredients used in skin external preparations such as conventional cosmetics, drugs, quasi-drugs, such as antioxidants, oils, ultraviolet protection agents, surfactants, thickeners, alcohols, powdered ingredients, colorants, aqueous ingredients, water, various skin nutrients, etc., may be appropriately mixed as needed without impairing the effects of the present invention.
[0191] The skin external preparation of the present invention can be used as a cosmetic, quasi-drug, etc. applied to the outer skin, and is particularly suitable for use as a cosmetic. Its dosage form is not limited as long as it can be applied to the skin. Any dosage form such as a solution system, a solubilization system, an emulsion system, a powder dispersion system, a water-oil two-layer system, a water-oil-powder three-layer system, an ointment, a lotion, a gel, an aerosol, etc. can be used.
[0192] When the preparation of the present invention is used as a cosmetic, it can be used in the form of lotion, emulsion, foundation, lipstick, lip balm, cleansing cream, massage cream, facial mask, hand cream, hand washing powder, bath liquid, body lotion, body cream, bath cosmetics, etc.
[0193] However, the forms that the preparations and compositions of the present invention can adopt are not limited to the above-mentioned dosage forms and forms. In addition, the preparations or compositions of the present invention can be used in combination with the device or method of the present invention or other devices or methods.
[0194] The object to which the method, device, preparation and composition of the present invention are applied may be an object in which skin photoaging and / or pigmentation (e.g., dermal pigmentation) is objectively or subjectively confirmed, or an object in which skin photoaging and / or pigmentation is desired to be prevented. For example, it may be an object judged to have a breakdown in the M1 / M2 balance. In one embodiment, it may be an object judged to have a high degree of skin photoaging and / or pigmentation (e.g., dermal pigmentation) using the M1 / M2 balance in the skin as an indicator. Alternatively, it may be an object that is concerned about a phenotype specific to skin photoaging, such as spots, wrinkles, sagging, etc., or an object that is concerned about epidermis, pigmentation, such as spots, dullness, birthmarks, traces of tattoos, etc. Spots, wrinkles, sagging, dullness, birthmarks, traces of tattoos, etc. may be determined by visual judgment and using known indicators.
[0195] In addition, the present invention also provides a method for screening anti-photoaging agents, which comprises the following steps: administering a candidate agent to a biological sample; measuring the M1 / M2 balance in the biological sample before and after the candidate agent is administered; when the M1 / M2 balance in the biological sample administered with the candidate agent is improved compared to before the agent is administered, the agent is evaluated as having an anti-photoaging and / or pigmentation inhibitory effect. A method for evaluating an anti-photoaging and / or pigmentation inhibitory cosmetic treatment is also provided, which comprises the following steps: administering a cosmetic treatment to a skin sample; measuring the M1 / M2 balance in the skin sample before and after the cosmetic treatment is performed; when the M1 / M2 balance in the skin sample administered with the cosmetic treatment is improved compared to before the treatment is performed, the treatment is evaluated as having an anti-photoaging and / or pigmentation inhibitory effect. The method of the present invention can be used to screen whether a candidate agent or cosmetic treatment has an anti-photoaging and / or pigmentation inhibitory effect, and product development and new skin care can be proposed. That is, the present invention provides an anti-photoaging agent and / or pigmentation inhibitor and an anti-photoaging and / or pigmentation inhibitor beauty treatment for preventing and / or improving photoaging and / or pigmentation by adjusting the M1 / M2 balance. The pigmentation may be dermal pigmentation.
[0196] Any sample such as a skin sample or an immune cell sample can be used as a biological sample. The skin sample can be a skin sample after collection, for example, a skin sample in an in vitro state after being collected from an animal such as a human, or a cultured skin cell, for example, a single-layer or multi-layer cultured cell, a cultured keratinocyte, or a cultured fibroblast in an in vitro state. Alternatively, it can be an artificial skin sample such as a 3D skin model. The immune cell sample can be an immune cell present in the skin after collection, an immune cell in the blood after the blood infiltrating the skin is collected, a cultured immune cell, or the like. Although there is no limitation on the 3D skin model, for example, it can be produced by the method described in Patent Document 8 and Non-Patent Documents 10 to 12, or it can be produced by changing such a method in order to facilitate the measurement of the M1 / M2 balance. There is no limitation on the biological sample as long as the M1 / M2 balance can be measured.
[0197] For example, the screening method for photoaging resistance and / or pigmentation inhibitors can be achieved by differentiating immune cells such as THP-1 into M0, adding a drug and culturing for a certain period of time, then recovering the culture supernatant, and using ELISA and other assays to quantify the amount of M2-specific cytokines such as IL-10. In such a screening method, as a positive control, cells differentiated into M2 by adding IL-4, IL-13, etc. can be used, and further, experiments in which candidate drugs are added to IL-4 and IL-13 can be compared. That is, M2 has a high IL-10 production capacity, so if the IL-10 in the supernatant increases after M0 differentiation compared to the control (control) cultured only with a culture medium, it can be said that it has differentiated into M2, and such a drug can be set as an "improving agent", wherein the presence or absence of the drug can be compared in the presence of IL-4, IL-13, etc. to evaluate whether the amount of IL-10 produces a difference.
[0198] The candidate drugs referred to in this specification refer to drugs that are investigated for their anti-photoaging and / or pigmentation inhibition effects, and include drugs that are already sold as products as well as drugs in the development stage. They can also be drugs that are selected for use as cosmetics during the development of cosmetics.
[0199] The beauty treatment is not particularly limited, and includes any treatment that is considered to be effective for inhibiting photoaging and / or pigmentation, such as the application of cosmetics containing the preparation of the present invention or other ingredients. The so-called cosmetics refer to cosmetics applied to the skin, such as lotions, emulsions, beauty essences, creams, foundations, etc., but are not limited to these. It means all substances that are applied to the skin even if the improvement of skin condition is not the direct purpose, for example, sunscreens, etc. Alternatively, the beauty treatment may be, for example, physical stimulation such as stretching stimulation, pressing stimulation, and massage applied to the skin. The beauty treatment may be a one-time treatment or a continuous treatment performed from several days to several weeks. The beauty treatment may be performed by an individual or in a beauty salon, a cosmetics sales store, a beauty salon, etc.
[0200] In addition, the present invention also provides a screening kit for photoaging and / or pigmentation inhibitors, including antibodies for detecting any markers such as CD86, CD206, CD163, etc., which can measure the number of M1 and M2, and agents for measuring the amount of mRNA of these markers. The present invention also provides the following methods, systems, and devices.
[0201] A method for evaluating the photoaging and / or pigmentation of an object's skin executed by one or more computers, comprising the following steps: a step of obtaining data regarding a preset reference value of the M1 / M2 balance of the skin; a step of obtaining data regarding the M1 / M2 balance of the object's skin; a step of performing calculations by comparing with the data regarding the M1 / M2 balance of the object's skin with reference to the reference value; a step of evaluating the photoaging and / or pigmentation of the skin based on the result calculated by the calculation step; and a step of displaying the result evaluated by the evaluation step.
[0202] A method for evaluating the photoaging and / or pigmentation of an object's skin, comprising the following steps: a step in which an analysis unit of a server analyzes the relationship between the M1 / M2 balance of the skin and the photoaging and / or pigmentation by machine learning using a method using a neural network, wherein the method using a neural network uses teacher data based on data on the M1 / M2 balance of the skin and the photoaging and / or pigmentation of the skin stored in a storage unit; a step in which a receiving unit of the server receives data on the M1 / M2 balance of the object's skin; and a step in which the evaluation unit of the server evaluates the photoaging and / or pigmentation of the object's skin based on the analyzed relationship and uses the received M1 / M2 balance of the object's skin as input and outputs the evaluation data.
[0203] A system for evaluating the photoaging and / or pigmentation of an object's skin, comprising: a database unit for storing data regarding a preset reference value of the M1 / M2 balance of the skin; a data input unit for inputting data regarding the M1 / M2 balance of the object's skin; a calculation unit for performing calculations by comparing the reference value stored in the above-mentioned database unit with the data regarding the M1 / M2 balance of the object's skin input through the above-mentioned data input unit; an evaluation unit for evaluating the photoaging and / or pigmentation of the above-mentioned skin based on the calculation result obtained by the above-mentioned calculation unit; and a display unit for displaying the result evaluated by the above-mentioned evaluation unit.
[0204] A device for calculating photoaging and / or pigmentation, which uses data on the M1 / M2 balance of the skin of the object to calculate the photoaging and / or pigmentation of the skin of the object, wherein the device comprises a calculation unit for calculating the photoaging and / or pigmentation of the object if data on the M1 / M2 balance of the skin of the object is input, and the calculation unit comprises a learned neural network that has implemented machine learning processing using teacher data so as to calculate the estimated photoaging and / or pigmentation when data on the M1 / M2 balance of the skin is input.
[0205] The method, system and device of the present invention can measure objective photoaging and / or pigmentation based on M / M2 balance.
[0206] Example
[0207] The present invention will be further described in detail below by way of examples, but the present invention is not limited thereto.
[0208] Experiment 1: Tissue staining
[0209] Will Figure 1a Cryosections were prepared from the skin of the eyelids of Caucasians of the indicated young age groups (20s to 30s) and elderly groups (60s to 70s) who had undergone photoaging, and the sections were sliced and stained with the following macrophage markers.
[0210] (1) Staining of M1 macrophages: Double staining was performed using goat anti-human CD86 antibody (R&D) and rabbit anti-human CD11b antibody (abcam). Figure 1b ).
[0211] (2) Staining of M2 macrophages: Double staining was performed using mouse anti-human CD206 antibody (BD) or mouse anti-human CD163 antibody (Leica) and rabbit anti-human CD11b antibody (abcam). Figure 1c ).
[0212] (3) Staining of total macrophages: Double staining was performed using mouse anti-human CD68 antibody (abcam) and rabbit anti-human CD11b antibody (abcam).
[0213] The cells that were doubly positive for the antibodies (1) to (3) up to 200 μm just below the epidermis were counted as individual macrophages ( Figure 1d In addition, to investigate the relationship between M1 and M2 macrophages and collagen production, double staining was performed using goat anti-human CD86 antibody (R&D) and rat anti-procollagen antibody (Millipore), or mouse anti-human CD206 antibody (BD) and rat anti-procollagen antibody (Millipore). Figure 1e Left).
[0214] The tissue staining of (1) to (3) is shown in Figure 1b In , c, the counting results are shown in Figure 1d The results of double staining with M1 and M2 macrophage antibodies and anti-procollagen antibodies are shown in Figure 1e Left center. Figure 1bAs shown in , c, and d, in elderly people who have undergone photoaging, a large number of M1 macrophages are observed, while the number of M2 macrophages decreases. More specifically, Figure 1b As shown in Figure 2, M1 macrophages are only present around blood vessels in young people, but are scattered throughout the tissues in elderly people. Figure 1c As shown in Figure 2, M2 macrophages are present throughout the tissues of young people, but their number is reduced in elderly people. Figure 1d As shown, the total number of macrophages (number of M1 + number of M2) did not change between young and old people, only the M1 / M2 balance changed. For young people, the ratio of M2 to M1 (number of M2 / number of M1) was in the range of about 5 / 5 to about 7 / 3, while for the elderly, the ratio of M2 to M1 decreased sharply, and the M1 / M2 balance was greatly broken, which was significantly different from the value of young people.
[0215] Further, if Figure 1e As shown in the two photos on the upper left, the positions of M1 macrophages and procollagen are shifted in both young and old individuals, while the positions of M2 macrophages and procollagen are consistent as shown in the two photos on the lower left. Figure 1e As shown in the schematic diagram on the right, M1 acts on fibroblasts in such a way that it promotes collagen destruction and M2 promotes collagen production.
[0216] Experiment 2: M1 and M2 differentiation stimulation experiment of THP-1
[0217] According to the method described in Non-Patent Document 1, THP-1, an established cell line of human origin, was used to induce differentiation into M1 and M2 macrophages. Figure 2a According to the method shown, THP-1 was cultured in RPMI1640 (Nakalai) with 1mM sodium pyruvate (Nakalai), 2mM L-glutamine (Nakalai), and 10% FBS. Then, 100nM PMA (abcam) was further added to stimulate for 24 hours to differentiate into macrophages. When differentiating into M1, 100ng / mL LPS (sigma) and 20ng / mL IFNγ (R&D) were further added to stimulate for 24 hours. When differentiating into M2, 20ng / ml IL-4 (R&D) and 20ng / mL IL13 (R&D) were further added to stimulate for 24 hours. Observation under a microscope, as shown in FIG. Figure 2b The morphological change was confirmed as shown.
[0218] In addition, mRNA was extracted from cells in the differentiated or undifferentiated state, and the expression levels were quantified by real-time PCR using probes for IL-1beta, TNF-alpha, and IL-10 (Applied Biosystems) using the TaqMan gene expression assay system ( Figure 2c Furthermore, the same PCR was performed using the same CD86 antibody (R&D) and CD206 antibody (BD) as in Experiment 1 to quantify the expression level ( Figure 2c The respective values were corrected with the mRNA expression level of GAPDH.
[0219] like Figure 2c As shown, it was shown that the macrophages differentiated by the method described in Experiment 2 produced inflammatory cytokines (IL-1beta, TNF-alpha) characteristic of M1 and anti-inflammatory cytokines (IL-10) characteristic of M2. Further, these differentiation-induced macrophages showed an increase in the expression of CD86 and CD206, which are surface markers of M1 and M2 macrophages, respectively. These results confirmed that the differentiation induction was successful. Therefore, the M1 and M2 macrophages differentiated by the method of Experiment 2 and the undifferentiated M0 macrophages were used in the following experiments 3 and 4.
[0220] Experiment 3: Addition of M1 and M2 macrophage supernatants to fibroblasts
[0221] like Figure 3a As shown, THP-1 was differentiated into M1 and M2 by the same method as in Experiment 2 or was left in an undifferentiated state of M0, the supernatant was removed, the cells were washed once with PBS, and then cultured in a culture medium for 48 hours. These supernatants containing secretions of M1 and M2 such as inflammatory / anti-inflammatory cytokines were added to neonatal fibroblasts. As a control, cells to which RPMI1640 (Nakalai) was added were used. After the addition of the supernatant, the fibroblasts were cultured for 72 hours, and the amount of procollagen in the supernatant was quantified using a PIP ELISA kit (TAKARA). Figure 3b The cell fractions were stained with rabbit anti-human collagen antibody (CEDERLANE) and biotinylated hyaluronan binding protein (HOKUDO). Figure 3c ). Furthermore, β-gal was used as an aging indicator. After the nuclei of the cells were stained with DAPI, the β-gal in the cells was stained using the Senescence Detection Kit (Aging Detection Kit, abcam) ( Figure 3d ), count the number of β-gal positive cells and DAPI positive cells ( Figure 3e).
[0222] Furthermore, in order to study the contribution of M1 macrophages and M2 macrophages to melanin production, the supernatant of each macrophage was added to fibroblasts for culture in the same manner as described above. Then, the fibroblasts were recovered and mRNA was recovered, and real-time PCR was performed using probes for HGF, ET1, bFGF, IL-1alpha, SCF, and clusterin to quantify the expression of each mRNA ( Figure 3f ).
[0223] The results are shown in Figure 3b~3f middle. Figure 3b The amounts of procollagen after adding the supernatant of each macrophage (M1, M2) to fibroblasts and culturing them for 72 hours are shown. Figure 3c The localization of collagen and hyaluronic acid in fibroblasts after adding the supernatant of each macrophage (M1, M2) and culturing for 72 hours is shown. Figure 3b , c It can be seen that M1 significantly inhibits collagen production. Figure 3d The intracellular β-gal in fibroblasts after adding the supernatant of each macrophage (M1, M2) and culturing for 72 hours is shown. Figure 3d This suggests that M1 increases β-gal-positive cells and promotes aging, whereas M2 inhibits aging. Figure 3e The graph shows the number of β-gal positive cells and DAPI positive cells counted. The right graph shows the total number of DAPI positive cells per well. Figure 3e The right figure shows that M2 not only inhibits cell aging but also promotes cell proliferation. Figure 3e The left figure shows the ratio (%) of the number of β-gal positive cells to the total number of DAPI positive cells, indicating that M1 has an aging and cell death promoting effect, while M2 has an aging inhibiting and cell proliferation effect. Figure 3f As shown, it can also be known that the mRNA expression of melanogenesis-related factors acts in the direction of increasing melanin production through M1, and on the other hand, acts in the direction of inhibiting melanin production through M2. As reported in non-patent literature 6, it is known that fibroblasts secrete factors such as SCF and HGF through light stimulation such as UV, causing cell death. In addition, as reported in non-patent literatures 7 to 9, fibroblasts secrete factors such as HGF, ET1, bFGF, SCF, clusterin, etc. through light stimulation, thereby directly or indirectly acting on melanocytes to produce melanin. Therefore, it is suggested that cell death and melanin production caused by light stimulation are caused by the collapse of the balance of M1 / M2.
[0224] Experiment 4: Addition of M1 and M2 macrophage supernatants to young and old fibroblasts
[0225] Next, in order to confirm whether the anti-aging effect of M2 macrophages is also effective for aged fibroblasts, that is, whether it has a rejuvenation effect, M1 and M2 macrophage supernatants were added to young and old cells, and the difference in the effect of macrophage supernatants caused by the difference in fibroblast age was studied.
[0226] Specifically, each macrophage supernatant collected by the same method as in Experiment 3 was added to fibroblasts derived from human foreskin of newborns (fibroblasts derived from young age) and fibroblasts derived from 68-year-old humans (fibroblasts derived from old age), and cultured for 72 hours. Then, β-gal and DAPI staining were performed by the same method as in Experiment 3, and the number of β-gal-positive cells and DAPI-positive cells was counted ( Figure 4a , 4b ). In addition, similarly to Experiment 3, the supernatants of M1 and M2 were added to fibroblasts of young and old origin, and the fibroblasts were cultured for 72 hours. The amount of procollagen in the supernatant was quantified using a PIP ELISA kit (TAKARA) ( Figure 4c ), stained with rabbit anti-human collagen antibody (CEDERLANE) and DAPI ( Figure 4d ).
[0227] Figure 4a The staining pattern for β-gal is shown. Figure 4b The graph shows the results of plotting the number of β-gal positive cells in young- and old-age-derived fibroblasts against the total number of cells per well. Figure 4a As shown in the figure below, even for aged cells, the number of β-gal-positive cells was significantly reduced by adding M2 supernatant, and aging was inhibited. Figure 4b It can also be seen that regardless of age, aging is promoted by M1 and inhibited by M2. Figure 4c As shown in , d, the results that the amount of collagen produced by cells supplemented with M1 supernatant was significantly lower than that of cells supplemented with M2 supernatant regardless of age also support the above conclusion.
[0228] Experiment 5: Co-culture of M1 macrophages, M2 macrophages and neonatal foreskin-derived fibroblasts
[0229] The amount of collagen produced when neonatal foreskin-derived blasts and the same number of M1 or M2 macrophages (produced by the method of Experiment 2) were cultured in RPMI1640 (Nakalai) and when neonatal foreskin-derived fibroblasts and half of the M1 or M2 macrophages were cultured in RPMI were stained with rabbit anti-human collagen antibody (CEDERLANE) and compared. Macrophages were also visualized by staining with mouse anti-human CD68 antibody (abcam).
[0230] The results are shown in Figure 5 In the case of neonatal foreskin-derived blasts, the addition of M1 supernatant also reduced collagen, while the addition of M2 produced a large amount of collagen. In other words, it was found that even in young cells, if the M1 / M2 balance is disrupted, collagen is affected.
[0231] Experiment 6: Effects of the Collapse of M1 / M2 Balance Using a 3D Skin Model
[0232] In order to study the effects of M1 / M2 macrophages on epidermal cells and fibroblasts, three types of 3D skin models consisting of three-layer structures as described in the following table were prepared.
[0233] Table 1
[0234]
[0235] The 3D skin model was prepared as follows. Human dermal fibroblasts (0.2×10 6 ), using 200 μM ascorbic acid-2-phosphate magnesium (APM), 10% FBS-DMEM, the medium was exchanged every 2 days and cultured for 1 week. On top of it, 0.5% type I collagen-10% FBS-DMEM solution containing human dermal fibroblasts was dispensed into the control model, and the above solution to which 30,000 cells of M1 macrophages and M2 macrophages differentiated by the method of Experiment 2 were further added was dispensed into the M1 model and the M2 model, respectively, and collagen gel was prepared on the human dermal fibroblasts and cultured for 1 to 5 days.
[0236] Furthermore, epidermal keratinocytes were dispersed in Humedia-KG2 (Kurabo) medium to a concentration of 5×10 5 Cells were seeded on the collagen gel at 1:1 ratio, and a medium prepared by mixing Humedia-KG2 and 10% FBS-DMEM at 1:1 and supplemented with 200 μM APM was added to the outside of the insert until the liquid level reached the same level as the inside, and the cells were cultured for 3 days.
[0237] Then, the medium in the insert or glass ring was removed, and 200 μM APM, 10 μM N-hydroxy-2-[[(4-methoxyphenyl)sulfonyl]3-picolyl)amino]-3-methylbutanamide hydrochloride (CGS27023A (MMP inhibitor)), and 10 μM BIPBIPU (heparanase inhibitor) were added to the skin model medium (10% FBS-DMEM and Humedia-KG2 EGF(-) mixed at a ratio of 1:1 to adjust Ca to 1.8 mM) to the height of the bottom surface of the insert, and the inside of the insert was exposed to air for air-liquid interface culture. The culture medium was exchanged every 2 to 3 days for 2 weeks.
[0238] After the cultured skin model was fixed with 4% PFA / PBS (Nakarai), it was stained with anti-CD206 antibody (abcam), anti-CD68 antibody (abcam), and anti-CD86 antibody (abcam) in the same manner as in Experiment 1 to confirm the presence of M1 and M2 macrophages ( Figure 6 Then, staining with anti-p21 antibody (abcam) and DAPI (VECTOR), the number of cells stained with DAPI in each of the epidermal cell layer and the fibroblast layer was set as the total cell number, and the number of cells stained with anti-p21 antibody was counted as the number of p21 positive cells. The ratio of the number of p21 positive cells to the total cell number was calculated by the following formula.
[0239] The ratio of p21 positive cells to total cells = (p21 positive cells / total cells) × 100 (%)
[0240] The results are shown in Figure 7 , 8 As shown in these figures, in both the epidermal cell layer in the upper layer connected to the middle layer and the fibroblast layer in the lower layer, p21-positive cells increased in the M1 model (M1) compared to the control model (cont), while they decreased in the M2 model (M2). This tendency is consistent with Experiment 3 using a monolayer culture. Therefore, in the 3D skin model that is closer to human skin, it is suggested that M1 macrophages have an aging and cell death promoting effect, while M2 macrophages have an aging and cell death inhibiting effect.
[0241] Experiment 7: Sunlight irradiation experiment using an in vitro model of human skin
[0242] NativeSkin (skin collected from a 38-year-old woman) manufactured by Genoskin was cultured for one day in the culture medium provided upon arrival. The next day, an optical filter was placed in a 1000W solar simulator manufactured by Oriel to conduct only UVA and UVB at 11.5 J / cm2 Irradiation was performed and the cells were cultured continuously with the attached culture medium (irradiation (+)). As a control, a sample that was not irradiated was used (irradiation (-)). The samples were collected 5 days after irradiation, and M1 macrophages, M2 macrophages, and total macrophages were stained in the same manner as in Experiment 1, and their numbers were counted and plotted.
[0243] The results are shown in Fig. 9 In the case of the solar simulator, the number of M1 increases the most. On the other hand, the increase in the number of M2 is very small compared to the case of M1. In other words, it can be seen that the balance of M1 / M2 is broken by light stimulation, and the ratio of M1 increases.
[0244] Experiment 8: Stretching stimulation experiment using an in vitro model of human skin
[0245] Next, methods for adjusting or improving the M1 / M2 balance were studied.
[0246] Sample: NativeSkin (skin collected from a 38-year-old woman) manufactured by Genoskin Co., Ltd. (6-hole size, approximately 2 to 2.5 cm in diameter) was used.
[0247] Stretching conditions: production Fig.11 The stretching device has a gripping part at both ends of the skin in the hole as shown in the figure, and the skin is stretched by stretching the gripping part. The hole with the tissue piece is set horizontally, and the gripping part is operated to stretch the skin from both ends, such as Fig.10 As shown, the sample was stretched at a rate of 10% / s to a stretch rate of 10%, and the sample was restored to its original non-stretched state at a recovery rate of 10% / s. This was set as 1 cycle, and a total of 90 cycles were performed over 30 minutes. The 90 cycles were set as 1 group, and a rest time of 30 minutes to 1 hour was set between groups, and a total of 3 groups (a total of 270 cycles) were performed over 3 hours. As a control, a sample (control) that was not subjected to stretching stimulation was used.
[0248] Observation method: For skin samples to which stretch stimulation was applied or not, only total macrophages were stained with rabbit-derived anti-human CD11b antibody (abcam), and M1 macrophages, M2 macrophages, and total macrophages were stained and counted by the same method as in Experiment 1. The ratio (%) of each macrophage (M1, M2) to the total number of macrophages was calculated and plotted.
[0249] The results are shown in Fig.12 Compared with the control, the total number of macrophages and the number of M1 in the sample to which stretch stimulation was applied did not change much, but the number of M2 increased significantly. In other words, it was found that the balance of M1 / M2 was improved by stretch stimulation.
[0250] Experiment 9: Screening of anti-photoaging and / or pigmentation agents that prevent and / or improve photoaging and / or pigmentation by adjusting or improving the M1 / M2 balance
[0251] Screening for drugs that adjust or improve the M1 / M2 balance was performed.
[0252] As screening target drugs, a total of 19 ingredients including Forsythia suspensa extract, thyme extract, and tranexamic acid amide (N-methyl-trans-4-(aminomethyl)cyclohexanecarboxamide) were studied. The Forsythia suspensa extract is an extract of the aerial part of Forsythia suspensa purchased from Ichimaru Furukos. The thyme extract is an extract of the whole plant of Asian thyme purchased from Xiangrong Industry. Tranexamic acid amide was synthesized by the method described in Patent Document 14. The Forsythia suspensa extract was dissolved in 50% ethanol, the thyme extract was dissolved in butylene glycol, and the tranexamic acid amide was dissolved in PBS.
[0253] The same THP-1 cells as in Experiment 2 were used as they were in the undifferentiated state of M0 and cultured at 37°C overnight. The above-mentioned screening agent was added in a manner of 0.1% of the Forsythia suspensa extract, 0.1% of the thyme extract, 0.06% and 0.03% of tranexamic acid carboxamide relative to the culture medium, and an equal amount of their solvents was added to the control, and cultured at 37°C for two nights. The cells were recovered and RNA was extracted, and the expression levels of CD86 and GAPDH were quantified by real-time PCR, and CD86 / GAPDH was measured. Agents that reproducibly reduced CD86 / GAPDH values compared to the control (cont) were explored as M1 differentiation inhibitors.
[0254] The results are shown in Fig.13 In. By Fig.13 It was shown that the CD86 / GAPDH value was significantly reduced when Forsythia suspensa extract, thyme extract, and tranexamic acid carboxamide were added, and it had an M1 differentiation inhibitory effect, suggesting that it can be used as an M1 / M2 balance regulator / improver.
[0255] Experiment 10: Screening of anti-photoaging agents that prevent and / or improve photoaging and / or pigmentation by adjusting or improving the M1 / M2 balance
[0256] In order to screen more drugs, a total of 8 kinds of ingredients including Phellodendron chinense extract and Eucalyptus extract were studied by the same method as Experiment 9. Phellodendron chinense extract used the dried product of Phellodendron chinense bark of Rutaceae, and Eucalyptus extract used the extract of eucalyptus leaves. Phellodendron chinense extract was dissolved in butylene glycol in a manner of 0.01%, and eucalyptus extract was dissolved in 50% ethanol in a manner of 0.1%. These solvents were used as controls.
[0257] The same method as in Experiment 9 was used to perform drug addition, cell recovery, RNA extraction, and CD86 / GAPDH measurement, and drugs that reproducibly reduced CD86 / GAPDH values compared to the control (cont) were searched as M1 differentiation inhibitors. The results are shown in Fig.15 In. By Fig.15 It is suggested that in addition to the drug in Experiment 9, Phellodendron chinense and Eucalyptus extracts can also be used as M1 / M2 balance adjusters / improvers.
[0258] Experiment 11: Effects of M1 and M2 macrophage supernatants on collagen
[0259] In addition to Experiment 3, in order to study the contribution of M1 macrophages and M2 macrophages to collagen degradation, the supernatant of each macrophage was added to fibroblasts and cultured in the same manner as Experiment 3, and mRNA was recovered after 72 hours. As an indicator of collagen degradation, real-time PCR was performed using probes for MMP-1, MMP-2, and IL-1β (Taqman probe manufactured by Applied Biosystems) to quantify the expression level of each mRNA ( Fig.16a ).
[0260] Furthermore, in order to study the contribution of M1 macrophages and M2 macrophages to collagen production / maturation, the supernatant of each macrophage was added to fibroblasts and cultured in the same manner as in Experiment 3, and mRNA was recovered after 72 hours. As an index of collagen production / maturation, real-time PCR was performed using probes for COL1A1, COL1A2, HSP47, and ADAMTS-2 (Taqman probe manufactured by Applied Biosystems), and the expression levels of each mRNA were quantified ( Fig.16b ).
[0261] Depend on Fig.16a , b It was confirmed that M1 contributes to collagen degradation, while M2 contributes to collagen production / maturation.
[0262] Experiment 12: Decomposition and production of collagen in an in vitro model using human skin of young and elderly people
[0263] Will Fig.17aThe skin of the temples of white people of the ages shown were made into frozen sections in the same way as in Experiment 1, and after cutting into thin sections, positive cells were counted using anti-procollagen antibodies (millipore) that stained the collagen fragments on the 3 / 4 side, anti-fragmented collagen (AdipoGen), and the same CD68, CD11b, CD206, and CD86 antibodies as in Experiment 1.
[0264] The results are shown in Fig.17b , c, d. In the older age group, the proportion of M1 macrophages was higher and the proportion of M2 macrophages was lower than that in the younger age group. However, regardless of age, there was a tendency that the number of macrophages showing 3 / 4 collagen-positive was larger than that of fibroblasts showing 3 / 4 collagen-positive, and the number of M2 macrophages showing 3 / 4 collagen-positive was larger than that of M1 macrophages showing 3 / 4 collagen-positive.
[0265] Experiment 13: In vitro experiment showing the uptake capacity of melanin in the dermis
[0266] The M1 macrophages and M2 macrophages obtained by differentiating THP-1 cells were differentiated by the same method as in Experiment 3. In each differentiated M1 macrophage, M2 macrophage, and fibroblast (manufactured by Kurabo), a melanin solution (Sigma, Melanin-BioReagent, Synthetic, suitable for cell culture) was dissolved in PBS and adjusted to 0.02% W / V for addition. After 24 hours, the cells were washed with PBS, photographed under a microscope, and the cells were recovered. The number of cells recovered was quantified by measuring the amount of melanin as follows using Alamar Blue (Life Technologies) .
[0267] Quantification of melanin:
[0268] After adding the culture medium of each cell (macrophage: RPMI1640, fibroblast: 1DMEM) adjusted to 1:10 Alamar blue, culture at 37°C for 30 minutes. Then, the supernatant 100ul / well was recovered, and the fluorescence was measured with Ascent (Thermo) at excitation / emission: 544nm / 590nm. After the measurement, it was washed with PBS, incubated at room temperature for 3 hours after adding 1M NaOH, and completely dissolved. The cell solution was measured at OD475 using POWERSCAN HT (DS PHARMABIOMEDICAL).
[0269] The results are shown in Fig.18a~c. The unit "Melanin / Alamar Blue" in the figure is the relative value ((2) / (1)) of the fluorescence intensity measured at 544nm / 590nm for the supernatant after staining the cultured cells with Alamar Blue, and the intensity measured at 475nm for the solution obtained by dissolving the cells and dissolving the melanin ((2)), indicating the melanin content per cell. As can be seen from these figures, M2 engulfs a lot of melanin. This tendency was observed after 24 hours, but the difference became more obvious after the cells were cultured for 5 days. Fig.18c ).
[0270] Experiment 14: In vitro experiment showing the uptake capacity of melanin in the dermis
[0271] Experiment 13 shows that M2 macrophages engulf more melanin than fibroblasts and M1 macrophages, so the dermis of human skin counted in Experiment 13 was observed in vitro using LSM880 (manufactured by Cartwright Corporation). It can be seen that when both old and young people are observed in the bright field, M2 macrophages are stained black together with melanin, while there is no melanin near M1 macrophages. Therefore, in vitro, it can be seen that M2 macrophages in the dermis take up more melanin than fibroblasts and M1 macrophages, and their number is counted and plotted ( Fig.19 ).
[0272] according to Fig.19 , the number of M2 macrophages that take up melanin is greater than the number of M1 macrophages in both the elderly and the young, and there is little age difference in this trend. This result suggests that it is M2 macrophages that take up melanin in the dermis, so if the proportion of M2 macrophages is increased and the M1 / M2 balance is adjusted, pigmentation in the dermis can be prevented and / or improved.
[0273] It was shown that the proportion of M1 increased due to photoaging (Experiment 7), and that the amount of skin collagen increased when the proportion of M2 was high (Experiments 11 and 12), and the pigment phagocytosis also tended to increase (Experiments 13 and 14). Therefore, it is suggested that the compounds of the present invention such as tranexamic acid carboxamide, which were screened as M1 differentiation inhibitors, thyme extract, phellodendron chinense, and eucalyptus extract, and the physical stimulation of the present invention that has an M1 / M2 balance improvement effect have high anti-photoaging and / or pigmentation inhibitory effects.
[0274] The above results suggest that, through light stimulation, an imbalance in the balance of M1 / M2 occurs, thereby causing photoaging in the skin exposed to light, or pigmentation in the dermis, but by adjusting or improving the balance of M1 / M2, photoaging and / or pigmentation in the dermis can be prevented and / or improved. The adjustment or improvement of the balance of M1 / M2 is achieved by applying stretching stimulation, pressing stimulation, and applying the compounds of the present invention such as tranexamic acid formamide, Forsythia suspensa extract, thyme extract, Phellodendron chinense, and / or eucalyptus extract, etc., which have an M1 differentiation inhibitory effect, as an M1 / M2 balance adjuster / improver, thereby expecting the prevention and / or improvement of photoaging and / or pigmentation in the dermis.
[0275] Industrial Availability
[0276] The present invention can be used to prevent and / or improve photoaging and / or dermal pigmentation, evaluate the degree of photoaging and / or dermal pigmentation, explore anti-photoaging and / or dermal pigmentation inhibitors and anti-photoaging and / or dermal pigmentation inhibitory cosmetic treatments.
Claims
1. A cosmetic method for preventing and / or improving photoaging and / or dermal pigmentation by adjusting the M1 / M2 balance, Adjusting the M1 / M2 balance comprises a process of applying a weak physical stimulus to the skin, wherein the process is achieved by applying a physical stimulus to the skin of the subject, wherein 10 to 500 cycles at a frequency of 0.1 Hz to 1 Hz are regarded as one group, and the group is repeated for 1 to 10 groups, wherein the cycle comprises the following steps: (a) stretching the skin of the subject to a stretching rate of 1.0% to 10.0% at a stretching speed of 0.3% / s to 10% / s; and (b) recovery from a stretch, in, The elongation is calculated by the following formula: In the formula, fixed point A and fixed point B are any positions on the epidermis or the substrate to which the epidermis is bonded, and a straight line passing through fixed point A and fixed point B is parallel to the stretching direction.
2. The method according to claim 1, wherein adjusting the M1 / M2 balance is to increase the ratio of M2 to M1.
3. A beauty device is a beauty device used to prevent and / or improve photoaging and / or dermal pigmentation by adjusting the M1 / M2 balance, The device comprises: a stimulus generating unit for generating physical stimulus, and a stimulation applying section for applying the physical stimulation generated by the stimulation generating section to the skin, in, The device is a device for performing a process of applying weak physical stimulation to the skin, wherein the process is to perform 10 to 500 cycles at a frequency of 0.1 Hz to 1 Hz as one group, and to perform the group 1 to 10 groups, wherein the cycle comprises the following steps: (a) stretching the skin at a stretching speed of 0.3% / s to 10% / s to a stretching rate of 1.0% to 10.0%; and (b) recovery from a stretch, The stretch rate is calculated by formula 1: In the formula, fixed point A and fixed point B are any positions on the epidermis or the substrate to which the epidermis is bonded, and a straight line passing through fixed point A and fixed point B is parallel to the stretching direction. 4 . The cosmetic device according to claim 1 , wherein adjusting the M1 / M2 balance is to increase the ratio of M2 to M1.
